Last reviewed · How we verify
Vortioxetine IV
At a glance
| Generic name | Vortioxetine IV |
|---|---|
| Sponsor | H. Lundbeck A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study
- A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects (PHASE1)
- Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) (PHASE3)
- Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder (PHASE2)
- Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |